e-learning
resources
Virtual 2020
Pre-Congress Content
Advances in asthma treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE)
X. Muñoz Gall (Barcelona, Spain), J. Dominguez Ortega (Madrid, Spain), S. Pascual Erquicia (Bilbao, Spain), C. Cabrera Lopez (Las Palmas de Gran Canaria, Spain), C. Martin Panadero (Madrid, Spain), G. Monteagudo Ruiz (Madrid, Spain), G. Resler (Madrid, Spain)
Source:
Virtual Congress 2020 – Advances in asthma treatment
Session:
Advances in asthma treatment
Session type:
E-poster session
Number:
2622
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
X. Muñoz Gall (Barcelona, Spain), J. Dominguez Ortega (Madrid, Spain), S. Pascual Erquicia (Bilbao, Spain), C. Cabrera Lopez (Las Palmas de Gran Canaria, Spain), C. Martin Panadero (Madrid, Spain), G. Monteagudo Ruiz (Madrid, Spain), G. Resler (Madrid, Spain). Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE). 2622
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment?
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Prevalence of oral corticosteroid use in the German severe asthma population
Source: ERJ Open Res, 5 (4) 00092-2019; 10.1183/23120541.00092-2019
Year: 2019
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR)
Source: Eur Respir J, 52 (2) 1701927; 10.1183/13993003.01927-2017
Year: 2018
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort
Source: International Congress 2018 – Clinical markers of asthma
Year: 2018
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß
2
-agonist use in asthma
Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019
Year: 2020
Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE)
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Oral corticosteroid use in Swedish and Finnish severe asthma patients
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Real-life effectiveness of omalizumab in difficult-to-treat
versus
severe asthma: a national cohort study in Belgium
Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018
Year: 2019
Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials
Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019
Year: 2019
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Oral steroid intervention in severe asthma: focus on phenotypes. Report from the bioair study
Source: Annual Congress 2009 - One size (does not) fit all: phenotyping and controlling asthma
Year: 2009
X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 379s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept